Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05392179 · ClinicalTrials.gov registry record · Phase 2
A Study in Subjects With Retinitis Pigmentosa
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT05392179: Completed Phase 2 study, sponsored by Aldeyra Therapeutics.
NCT05392179 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05392179, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
Primary Outcome
The proportion of subjects that experience at least one serious adverse event
Interventions
- DRUG ADX-2191
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2023-06-23 |
| Phase | Phase 2 |
What the finished NCT05392179 record still lists
NCT05392179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which ADX-2191 is the first listed.
NCT05392179 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05392179 about?
NCT05392179 is a clinical study titled "A Study in Subjects With Retinitis Pigmentosa". An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
What is the current status of trial NCT05392179?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-07-14. Estimated completion is 2023-06-23.
What interventions are being tested in trial NCT05392179?
The interventions under investigation include: ADX-2191 (DRUG).
Who is sponsoring clinical trial NCT05392179?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05392179's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI